CONSORT-EHEALTH (V 1.6.1) -Submission/Publication Form

The CONSORT-EHEALTH checklist is intended for authors of randomized trials evaluating web-based and Internet-based applications/interventions, including mobile interventions, electronic games (incl multiplayer games), social media, certain telehealth applications, and other interactive and/or networked electronic applications. Some of the items (e.g. all subitems under item 5 - description of the intervention) may also be applicable for other study designs.

The goal of the CONSORT EHEALTH checklist and guideline is to be a) a guide for reporting for authors of RCTs, b) to form a basis for appraisal of an ehealth trial (in terms of validity)

CONSORT-EHEALTH items/subitems are MANDATORY reporting items for studies published in the Journal of Medical Internet Research and other journals / scientific societies endorsing the checklist.

Items numbered 1., 2., 3., 4a., 4b etc are original CONSORT or CONSORT-NPT (nonpharmacologic treatment) items. Items with Roman numerals (i., ii, iii, iv etc.) are CONSORT-EHEALTH extensions/clarifications.

As the CONSORT-EHEALTH checklist is still considered in a formative stage, we would ask that you also RATE ON A SCALE OF 1-5 how important/useful you feel each item is FOR THE PURPOSE OF THE CHECKLIST and reporting guideline (optional).

Mandatory reporting items are marked with a red *.

In the textboxes, either copy & paste the relevant sections from your manuscript into this form - please include any quotes from your manuscript in QUOTATION MARKS, or answer directly by providing additional information not in the manuscript, or elaborating on why the item was not relevant for this study.

YOUR ANSWERS WILL BE PUBLISHED AS A SUPPLEMENTARY FILE TO YOUR PUBLICATION IN JMIR AND ARE CONSIDERED PART OF YOUR PUBLICATION (IF ACCEPTED).

Please fill in these questions diligently. Information will not be copyedited, so please use proper spelling and grammar, use correct capitalization, and avoid abbreviations.

DO NOT FORGET TO SAVE AS PDF _AND_ CLICK THE SUBMIT BUTTON SO YOUR ANSWERS ARE IN OUR DATABASE !!!

Citation Suggestion (if you append the pdf as Appendix we suggest to cite this paper in the caption):

Eysenbach G, CONSORT-EHEALTH Group

CONSORT-EHEALTH: Improving and Standardizing Evaluation Reports of Web-based and Mobile Health Interventions

J Med Internet Res 2011;13(4):e126

1

CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form URL: http://www.jmir.org/2011/4/e126/ doi: 10.2196/jmir.1923 PMID: 22209829 jurkoel@gmail.com Ander account Concept opgeslagen Niet gedeeld * Verplichte vraag Your name * First Last Jurrijn Koelen

Primary Affiliation (short), City, Country * University of Toronto, Toronto, Canada

University of Amsterdam, the Netherlands

Your e-mail address * abc@gmail.com

j.a.koelen@utwente.nl

Title of your manuscript *

Provide the (draft) title of your manuscript.

Web-Based Human-Guided or Computer-Guided Transdiagnostic Cognitive Behavioral Therapy in University Students with Anxiety and Depression: Randomized Controlled Trial

Name of your App/Software/Intervention *

If there is a short and a long/alternate name, write the short name first and add the long name in brackets.

Minddistrict

Evaluated Version (if any)

e.g. "V1", "Release 2017-03-01", "Version 2.0.27913"

Jouw antwoord

Language(s) *

What language is the intervention/app in? If multiple languages are available, separate by comma (e.g. "English, French")

Dutch, English

URL of your Intervention Website or App

e.g. a direct link to the mobile app on app in appstore (itunes, Google Play), or URL of the website. If the intervention is a DVD or hardware, you can also link to an Amazon page.

https://www.minddistrict.com/

URL of an image/screenshot (optional)

Jouw antwoord

Accessibility *

Can an enduser access the intervention presently?

) access is free and open



) access is open to everyone, but requires payment/subscription/in-app purchases

) app/intervention no longer accessible

Anders: Available for research purposes only

Primary Medical Indication/Disease/Condition *

e.g. "Stress", "Diabetes", or define the target group in brackets after the condition, e.g. "Autism (Parents of children with)", "Alzheimers (Informal Caregivers of)"

Depressive or anxious complaints

Primary Outcomes measured in trial * comma-separated list of primary outcomes reported in the trial

PHQ-9, GAD-7

Secondary/other outcomes Are there any other outcomes the intervention is expected to affect?

AUDIT-C, DAST-10, health (VAS)

Recommended "Dose" * What do the instructions for users say on how often the app should be used?									
0	Approximately Daily								
	Approximately Weekly								
0	Approximately Monthly								
0	Approximately Yearly								
0	"as needed"								
0	Anders:								

Approx. Percentage of Users (starters) still using the app as recommended after * 3 months

d

- 0-10%
- 11-20%
- 21-30%
- 31-40%
- 41-50%
- 51-60%
- 61-70%
- 71%-80%
- 81-90%
- 91-100%
- Anders:

Overall, was the app/intervention effective? *
yes: all primary outcomes were significantly better in intervention group vs control
O partly: SOME primary outcomes were significantly better in intervention group vs control
o statistically significant difference between control and intervention
O potentially harmful: control was significantly better than intervention in one or more outcomes
O inconclusive: more research is needed
O Anders:
Article Preparation Status/Stage * At which stage in your article preparation are you currently (at the time you fill in this form)
O not submitted yet - in early draft status
O not submitted yet - in late draft status, just before submission

- Submitted to a journal but not reviewed yet
- submitted to a journal and after receiving initial reviewer comments
- submitted to a journal and accepted, but not published yet
 -) published
 - Anders:

Journal *

If you already know where you will submit this paper (or if it is already submitted), please provide the journal name (if it is not JMIR, provide the journal name under "other")

- Journal of Medical Internet Research (JMIR)
- JMIR mHealth and UHealth
- JMIR Serious Games
- JMIR Mental Health
- JMIR Public Health
- JMIR Formative Research
- Other JMIR sister journal
- Anders:

Is this a full powered effectiveness trial or a pilot/feasibility trial? *

) Pilot/feasibility

Fully powered

Manuscript tracking number *

If this is a JMIR submission, please provide the manuscript tracking number under "other" (The ms tracking number can be found in the submission acknowledgement email, or when you login as author in JMIR. If the paper is already published in JMIR, then the ms tracking number is the four-digit number at the end of the DOI, to be found at the bottom of each published article in JMIR)

no ms number (yet) / not (yet) submitted to / published in JMIR

Anders:

TITLE AND ABSTRACT

1a) TITLE: Identification as a randomized trial in the title

1a) Does your paper address CONSORT item 1a? *


I.e does the title contain the phrase "Randomized Controlled Trial"? (if not, explain the reason under "other")

🌒 yes

) Anders:

1a-i) Identify the mode of delivery in the title

Identify the mode of delivery. Preferably use "web-based" and/or "mobile" and/or "electronic game" in the title. Avoid ambiguous terms like "online", "virtual", "interactive". Use "Internet-based" only if Intervention includes non-web-based Internet components (e.g. email), use "computer-based" or "electronic" only if offline products are used. Use "virtual" only in the context of "virtual reality" (3-D worlds). Use "online" only in the context of "online support groups". Complement or substitute product names with broader terms for the class of products (such as "mobile" or "smart phone" instead of "iphone"), especially if the application runs on different platforms.



Does your paper address subitem 1a-i?*

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Web-Based Human-Guided or Computer-Guided Transdiagnostic Cognitive Behavioral Therapy"

1a-ii) Non-web-based components or important co-interventions in title Mention non-web-based components or important co-interventions in title, if any (e.g., "with telephone support").									
with telephone support).									
1 2 3 4 5									
subitem not at all important	۲	0	0	0	0	essential			
Selectie wissen									
Does your paper address subitem 1a-ii?									

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No, this was not addressed, as it was not a key component of the intervention.

1a-iii) Primary condition or target group in the title

Mention primary condition or target group in the title, if any (e.g., "for children with Type I Diabetes") Example: A Web-based and Mobile Intervention with Telephone Support for Children with Type I Diabetes: Randomized Controlled Trial

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
					S	electie wissen

Does your paper address subitem 1a-iii? *

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"University Students with Anxiety and/or Depression"

1b) ABSTRACT: Structured summary	of trial design,	methods,	results,	and
conclusions				

NPT extension: Description of experimental treatment, comparator, care providers, centers, and blinding status.

1b-i) Key features/functionalities/components of the intervention and comparator in the METHODS section of the ABSTRACT

Mention key features/functionalities/components of the intervention and comparator in the abstract. If possible, also mention theories and principles used for designing the site. Keep in mind the needs of systematic reviewers and indexers by including important synonyms. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
					S	electie wissen

Does your paper address subitem 1b-i?*

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Participants (...) were randomized to one of three conditions: (1) human-guided (HG) iCBT, (2) computer-guided (CG) iCBT, and (3) CAU."

1b-ii) Level of human involvement in the METHODS section of the ABSTRACT

Clarify the level of human involvement in the abstract, e.g., use phrases like "fully automated" vs. "therapist/nurse/care provider/physician-assisted" (mention number and expertise of providers involved, if any). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
					S	electie wissen


Does your paper address subitem 1b-ii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"To potentially demonstrate: (1) the superiority of two variants of a transdiagnostic iCBT program (human-guided and computer-guided iCBT) over care as usual (CAU)"

1b-iii) Open vs. closed, web-based (self-assessment) vs. face-to-face assessments in the METHODS section of the ABSTRACT

Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic or a closed online user group (closed usergroup trial), and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment). Clearly say if outcomes were self-assessed through questionnaires (as common in web-based trials). Note: In traditional offline trials, an open trial (open-label trial) is a type of clinical trial in which both the researchers and participants know which treatment is being administered. To avoid confusion, use "blinded" or "unblinded" to indicated the level of blinding instead of "open", as "open" in web-based trials usually refers to "open access" (i.e. participants can self-enrol). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)




Does your paper address subitem 1b-iii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No this was not mentioned in the abstract.

1b-iv) RESULTS section in abstract must contain use data

Report number of participants enrolled/assessed in each group, the use/uptake of the intervention (e.g., attrition/adherence metrics, use over time, number of logins etc.), in addition to primary/secondary outcomes. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)



Does your paper address subitem 1b-iv?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Significant differences were found in terms of adherence, indicating that participants in the HG condition did more sessions than in the CG condition (P = .002)."

1b-v) CONCLUSIONS/DISCUSSION in abstract for negative trials

Conclusions/Discussions in abstract for negative trials: Discuss the primary outcome - if the trial is negative (primary outcome not changed), and the intervention was not used, discuss whether negative results are attributable to lack of uptake and discuss reasons. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)



Does your paper address subitem 1b-v?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No this was not addressed as this was not a negative trial.

INTRODUCTION

2a) In INTRODUCTION: Scientific background and explanation of rationale

2a-i) Problem and the type of system/solution

Describe the problem and the type of system/solution that is object of the study: intended as stand-alone intervention vs. incorporated in broader health care program? Intended for a particular patient population? Goals of the intervention, e.g., being more cost-effective to other interventions, replace or complement other solutions? (Note: Details about the intervention are provided in "Methods" under 5)

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
					S	electie wissen


Does your paper address subitem 2a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The aim of the current study was twofold: (1) to examine the efficacy of a transdiagnostic iCBT program in a large sample of students with mild, moderate or severe levels of anxiety and/or depression, when compared to CAU and (2) to examine whether the addition of human guidance (HG) resulted in greater efficacy when compared to computerized guidance (CG)."

2a-ii) Scientific background, rationale: What is known about the (type of) system

Scientific background, rationale: What is known about the (type of) system that is the object of the study (be sure to discuss the use of similar systems for other conditions/diagnoses, if appropiate), motivation for the study, i.e. what are the reasons for and what is the context for this specific study, from which stakeholder viewpoint is the study performed, potential impact of findings [2]. Briefly justify the choice of the comparator.



Does your paper address subitem 2a-ii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The current study built upon a previous study comparing a human-guided (transdiagnostic) iCBT against CAU in a relatively small sample of students (n = 100). This previous study yielded no significant differences between conditions on any of the examined outcomes, at any of the time points (including 6 and 12-month follow-up), which may in part be attributable to limited power to detect small effects [10]. Also, this previous study included only students with mild to moderate anxiety and/or depression symptoms. As other iCBT trials indicate that interventions are more efficacious when offered to individuals with higher levels of anxiety and/or depression beyond mild symptoms in the current study."

2b) In INTRODUCTION: Specific objectives or hypotheses

Does your paper address CONSORT subitem 2b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"It was expected that: (a) individuals who followed either HG or CG would improve more than CAU on the primary outcomes of depression and anxiety at posttreatment, and (b) that individuals who followed HG would improve more on the primary measures compared to CG. Exploratory analyses were performed up until 6 and 12 months after baseline (post-randomization), and for the secondary outcomes. Higher adherence rates were expected for the HG compared to the CG condition [28]."

METHODS

3a) Description of trial design (such as parallel, factorial) including allocation ratio

Does your paper address CONSORT subitem 3a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The present study was a three-arm randomized control superiority trial conducted at the University of Amsterdam (UvA) in the Netherlands. "

3b) Important changes to methods after trial commencement (such as eligibility criteria), with reasons

Does your paper address CONSORT subitem 3b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

There were no such changes

3b-i) Bug fixes, Downtimes, Content Changes

Bug fixes, Downtimes, Content Changes: ehealth systems are often dynamic systems. A description of changes to methods therefore also includes important changes made on the intervention or comparator during the trial (e.g., major bug fixes or changes in the functionality or content) (5-iii) and other "unexpected events" that may have influenced study design such as staff changes, system failures/downtimes, etc. [2].

	1	2	3	4	5	
subitem not at all important	0	0	۲	0	0	essential
					S	electie wissen

Does your paper address subitem 3b-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No, as there were no such events that required fixing.

4a) Eligibility criteria for participants

Does your paper address CONSORT subitem 4a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Participants were (young) adults who were enrolled as Bachelor, Master, or PhD students at the University of Amsterdam (UvA). Before inclusion in the RCT, students participated in an eSurvey to screen for elevation of symptoms of anxiety and/or depression (mild, moderate or severe) [30]. Students were recruited between February 2019, and March 2022 and were included in the RCT based on the following inclusion criteria: (1) 16 years or older, and (2) mild, moderate, or severe symptoms of depression (as defined by a score within the range of 15 to 60 points on the Center for Epidemiological Studies Depression Scale (CES-D) [31] and/or anxiety (as defined by scoring above the cut-off score of 4 on the Generalized Anxiety Disorder scale - 7 items (GAD-7) [32] on the eSurvey."

4a-i) Computer / Internet literacy

Computer / Internet literacy is often an implicit "de facto" eligibility criterion - this should be explicitly clarified.




Does your paper address subitem 4a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Other than "Having slow or no internet connection" as exclusion, this was not explicitly addressed.

4a-ii) Open vs. closed, web-based vs. face-to-face assessments:

Open vs. closed, web-based vs. face-to-face assessments: Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic, and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment), i.e., to what degree got the study team to know the participant. In online-only trials, clarify if participants were quasi-anonymous and whether having multiple identities was possible or whether technical or logistical measures (e.g., cookies, email confirmation, phone calls) were used to detect/prevent these.



Does your paper address subitem 4a-ii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Students enrolled at the University of Amsterdam (UvA) received an invitation via email from the secured, central research-dedicated platform (LOTUS)." Participants were quasi-anonymous, yet measures were taken to prevent the possibility of having multiple identities (all access was secured, and/or linked to personal e-mail addresses).

4a-iii) Information giving during recruitment

Information given during recruitment. Specify how participants were briefed for recruitment and in the informed consent procedures (e.g., publish the informed consent documentation as appendix, see also item X26), as this information may have an effect on user self-selection, user expectation and may also bias results.

	1	2	3	4	5	
subitem not at all important	0	0	۲	0	0	essential
					S	electie wissen

Does your paper address subitem 4a-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Participants who scored above the cut-off (see above) on either anxiety and/or depressive symptoms received an email with an online information brochure and informed consent document." Moreover, participants were briefly informed about treatment conditions during the pre-treatment interview. "Participants were informed about the three conditions and whether they were assigned to either an intervention condition or CAU."

4b) Settings and locations where the data were collected

Does your paper address CONSORT subitem 4b? *


Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Apart from the pre-treatment interview, which take place over the telephone, all data were gathered online.

4b-i) Report if outcomes were (self-)assessed through online questionnaires Clearly report if outcomes were (self-)assessed through online questionnaires (as common in web-based trials) or otherwise.								
	1	2	3	4	5			
subitem not at all important	0	0	0	0	۲	essential		
					S	electie wissen		
Does your paper address subitem 4b-i? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study								
"The assessments were all conducted online and were not accessible for the psychologists (i.e., blinded), except for the pre-session questions that were available through the intervention platform."								

4b-ii) Report how institutional affiliations are displayed

Report how institutional affiliations are displayed to potential participants [on ehealth media], as affiliations with prestigious hospitals or universities may affect volunteer rates, use, and reactions with regards to an intervention.(Not a required item – describe only if this may bias results)



Does your paper address subitem 4b-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

All e-mail communications with the participants contained a university logo.

5) The interventions for each group with sufficient details to allow replication, including how and when they were actually administered

5-i) Mention names, credential, affiliations of the developers, sponsors, and owners Mention names, credential, affiliations of the developers, sponsors, and owners [6] (if authors/evaluators are owners or developer of the software, this needs to be declared in a "Conflict of interest" section or mentioned elsewhere in the manuscript).

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
						Selectie wissen

Does your paper address subitem 5-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

We refer to the developers of the intervention, and the sponsors, yet there is no conflict of interest to declare.

5-ii) Describe the history/development process

Describe the history/development process of the application and previous formative evaluations (e.g., focus groups, usability testing), as these will have an impact on adoption/use rates and help with interpreting results.




Does your paper address subitem 5-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No, this does not apply, as the intervention had already been tested in different populations.

5-iii) Revisions and updating

Revisions and updating. Clearly mention the date and/or version number of the application/intervention (and comparator, if applicable) evaluated, or describe whether the intervention underwent major changes during the evaluation process, or whether the development and/or content was "frozen" during the trial. Describe dynamic components such as news feeds or changing content which may have an impact on the replicability of the intervention (for unexpected events see item 3b).



Does your paper address subitem 5-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The content of the intervention was frozen during the trial.

5-iv) Quality assurance metho	ods					
Provide information on quality a information provided [1], if appli		e method	ls to ens	ure accu	racy and	quality of
	1	2	3	4	5	
subitem not at all important	0	0	0	۲	0	essential
					S	electie wissen

Does your paper address subitem 5-iv?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

A treatment integrity check did not formally take place, as the intervention was highly structured, and the feedback to participants was largely standardized. There was regular supervision by an experienced (PhD level) clinical psychologist.

5-v) Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used

Ensure replicability by publishing the source code, and/or providing screenshots/screencapture video, and/or providing flowcharts of the algorithms used. Replicability (i.e., other researchers should in principle be able to replicate the study) is a hallmark of scientific reporting.

	1	2	3	4	5	
subitem not at all important	0	0	۲	0	0	essential
					S	electie wissen

Does your paper address subitem 5-v?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

We have not provided source codes for data analysis, visual documentation of the intervention, and algorithm flowcharts. The source codes for data analysis are available upon request.

5-vi) Digital preservation

Digital preservation: Provide the URL of the application, but as the intervention is likely to change or disappear over the course of the years; also make sure the intervention is archived (Internet Archive, <u>webcitation.org</u>, and/or publishing the source code or screenshots/videos alongside the article). As pages behind login screens cannot be archived, consider creating demo pages which are accessible without login.




Does your paper address subitem 5-vi?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This item was not addressed. Examples from the intervention platform are still available from the developers.

5-vii) Access

Access: Describe how participants accessed the application, in what setting/context, if they had to pay (or were paid) or not, whether they had to be a member of specific group. If known, describe how participants obtained "access to the platform and Internet" [1]. To ensure access for editors/reviewers/readers, consider to provide a "backdoor" login account or demo mode for reviewers/readers to explore the application (also important for archiving purposes, see vi).




Does your paper address subitem 5-vii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The participants who were randomized to either intervention were instructed to create an account on the intervention platform (Minddistrict)." The access was contingent upon them creating a personal account and login, so this was secured.

5-viii) Mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework

Describe mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework [6] used to design them (instructional strategy [1], behaviour change techniques, persuasive features, etc., see e.g., [7, 8] for terminology). This includes an in-depth description of the content (including where it is coming from and who developed it) [1]," whether [and how] it is tailored to individual circumstances and allows users to track their progress and receive feedback" [6]. This also includes a description of communication delivery channels and – if computer-mediated communication is a component – whether communication was synchronous or asynchronous [6]. It also includes information on presentation strategies [1], including page design principles, average amount of text on pages, presence of hyperlinks to other resources, etc. [1].



Does your paper address subitem 5-viii? *


Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

" For the current study, we created a second English version of the intervention for PhD students that included a small adaptation of the examples to match their situation. The intervention is based on principles from cognitive behavior therapy for anxiety and depression and includes online exercises and homework assignments. The intervention comprised seven regular sessions (45 - 60 minutes per session) and one booster session (4 weeks after the completion of the last session). From the second session onward, participants were able to follow eight additional optional modules based on their personal needs, including sleep, perfectionism, alcohol use, rumination, self-worth, acceptance, appreciation and gratitude, and rest and relaxation. In sessions five and six, participants could decide to either engage in content directed at changing negative cognitions or at exposure to fear situations. They could decide to choose one additional module per session, and they were free to repeat this module or choose other modules in later sessions. "

"During the intervention, participants in both online conditions received support in the form of brief standardized emails (reminders) in the chat function of the online environment in case they were inactive. Participants received up to three weekly reminders by e-mail. Moreover, participants in both online conditions could use the chat/messaging function to ask technical or user-related questions (e.g., problems getting online access). Participants in the CG condition received automatically generated feedback messages upon completion of a module with the main aim of motivating students to carry on. In contrast, in the HG condition, the online counselors provided detailed therapeutic feedback based on the student's output of the modules."

5-ix) Describe use parameters

Describe use parameters (e.g., intended "doses" and optimal timing for use). Clarify what instructions or recommendations were given to the user, e.g., regarding timing, frequency, heaviness of use, if any, or was the intervention used ad libitum.



Does your paper address subitem 5-ix?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes: "It was advised to do at least one and no more than two treatment sessions per week."

5-x) Clarify the level of human involvement

Clarify the level of human involvement (care providers or health professionals, also technical assistance) in the e-intervention or as co-intervention (detail number and expertise of professionals involved, if any, as well as "type of assistance offered, the timing and frequency of the support, how it is initiated, and the medium by which the assistance is delivered". It may be necessary to distinguish between the level of human involvement required for the trial, and the level of human involvement required for a routine application outside of a RCT setting (discuss under item 21 – generalizability).



Does your paper address subitem 5-x?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes: "The counselors spent approximately thirty minutes on providing feedback per session. On average, participants received feedback 3.9 days (SD = 2.0; range 0-12 days) after they completed their session. The online counselors were 6 female BA-level psychologists, 5 female and one male MA-level psychologist, and one male PhD-level health care psychologist with over 10 years of prior clinical experience, who also supervised the online guidance and baseline intakes on a weekly basis. "

"First, it could be a result of the fact that the intensity of guidance in both conditions was quite similar. Although students in the HG condition received weekly personalized feedback from psychologists, students in the CG condition received a considerable amount of support as well, including automated feedback, regular reminders sent by a psychologist, personalized responses to queries in the chat, and phone calls in case of suicide alerts."

5-xi) Report any prompts/reminders used

Report any prompts/reminders used: Clarify if there were prompts (letters, emails, phone calls, SMS) to use the application, what triggered them, frequency etc. It may be necessary to distinguish between the level of prompts/reminders required for the trial, and the level of prompts/reminders for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

	1	2	3	4	5	
subitem not at all important	0	0	0	۲	0	essential
					S	electie wissen

Does your paper address subitem 5-xi? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes: "During the intervention, participants in both online conditions received support in the form of brief standardized emails (reminders) in the chat function of the online environment in case they were inactive. Participants received up to three weekly reminders by e-mail. "

5-xii) Describe any co-interventions (incl. training/support)

Describe any co-interventions (incl. training/support): Clearly state any interventions that are provided in addition to the targeted eHealth intervention, as ehealth intervention may not be designed as stand-alone intervention. This includes training sessions and support [1]. It may be necessary to distinguish between the level of training required for the trial, and the level of training for a routine application outside of a RCT setting (discuss under item 21 – generalizability.



Does your paper address subitem 5-xii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes: "Participants in the CAU condition were informed about and/or referred to conventional care services, both internal and external to the UvA. It should be noted that information about the available services was also provided to participants in both intervention groups. However, students in the CAU group were strongly advised to seek support. (Medical) health services used during the trial were monitored in all groups through self-report questions at post-treatment (t3), 6-month follow-up (t4), and 12-month follow-up (t5)."

6a) Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed

Does your paper address CONSORT subitem 6a? *


Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes: "The primary outcome measures were the PHQ-9 and the GAD-7, which both have good psychometric properties and are often used in the context of online interventions. "

"Participants were followed up to 12 months post-randomization. Measurements were administered at baseline (t1), mid-treatment (5 weeks post-randomization); t2), post-treatment (8 weeks post-randomization; t3), six months follow-up (t4), and 12 months follow-up (t5). "

6a-i) Online questionnaires: describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed

If outcomes were obtained through online questionnaires, describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed [9].



Does your paper address subitem 6a-i?

Copy and paste relevant sections from manuscript text

Yes, we applied the CHERRIES items, with respect to coverage, handling missing data, platforms used by participants to access the online questionnaire (end-user technology), randomization, etc, throughout the text.

Here is an example: "LOTUS contained the students' e-mail addresses, from which links for the e-survey platform Qualtrics, and other messages, were sent, depending on the phase of the study and the forms completed. The invitation email contained general information about the study and a unique link. Participants who clicked on the invitation link were referred to the e-survey platform. Here, they could find an information letter and were asked to give informed consent and complete the survey."

6a-ii) Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored

Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored (logins, logfile analysis, etc.). Use/adoption metrics are important process outcomes that should be reported in any ehealth trial.

	1	2	3	4	5	
subitem not at all important	0	0	0	۲	0	essential
					S	Selectie wissen

Does your paper address subitem 6a-ii?

Copy and paste relevant sections from manuscript text

Yes, as use was defined in two different ways: the average number of sessions done, and the number of participants completed the whole intervention.

"Finally, treatment adherence was measured by tracking the activities in Minddistrict. As outcome measures, we collected the average number of sessions completed and whether participants completed all sessions or not."

6a-iii) Describe whether, how, and when qualitative feedback from participants was obtained									
Describe whether, how, and when qualitative feedback from participants was obtained (e.g., through emails, feedback forms, interviews, focus groups).									
1	2	3	4	5					
0	0	0	۲	0	essential				
					Selectie wissen				
	qualitati ms, inte	qualitative feedb ms, interviews, f	qualitative feedback from ms, interviews, focus gro	qualitative feedback from particip rms, interviews, focus groups). 1 2 3 4	qualitative feedback from participants v rms, interviews, focus groups). 1 2 3 4 5				

Does your paper address subitem 6a-iii?

Copy and paste relevant sections from manuscript text

Yes, we assessed how satisfied the users were with a standardized questionnaire: "Client satisfaction was assessed posttreatment with the Client Satisfaction Questionnaire (CSQ-8) [45]."

6b) Any changes to trial outcomes after the trial commenced, with reasons

Does your paper address CONSORT subitem 6b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No, there were no changes to trial outcomes, this was pre-registered.

7a) How sample size was determined NPT: When applicable, details of whether and how the clustering by care provides or centers was addressed

7a-i) Describe whether and how expected attrition was taken into account when calculating the sample size								
Describe whether and how expected attrition was taken into account when calculating the sample size.								
	1	2	3	4	5			
subitem not at all important	0	0	0	۲	0	essential		
					S	electie wissen		

Does your paper address subitem 7a-i?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, drop out was taken into account while calculating the sample size. This was addressed in our paper: "Our a priori power calculations were based on the mixed factors 3×3 interaction difference between the three treatment arms and three-time points (baseline, mid-treatment, and post-treatment), and taking a dropout rate of 35% into account, as well as a correlation between repeated measures of r = 0.50). "

7b) When applicable, explanation of any interim analyses and stopping guidelines

Does your paper address CONSORT subitem 7b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Interim analyses were performed for the trial register, yet there were no stopping rules. The trial was conducted as anticipated.

8a) Method used to generate the random allocation sequence NPT: When applicable, how care providers were allocated to each trial group

Does your paper address CONSORT subitem 8a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Randomization was based on computer-generated random numbers."

8b) Type of randomisation; details of any restriction (such as blocking and block size)

Does your paper address CONSORT subitem 8b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes: "Participants were stratified by gender and anxiety and/or depressive symptoms to guarantee an even distribution of males/females and symptom severity across conditions."

9) Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned

Does your paper address CONSORT subitem 9?*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Allocation was concealed from psychologists involved in this study; two of the psychologists who provided guidance were also administrators with access to the backend of the software."

10) Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions

Does your paper address CONSORT subitem 10? *


Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Allocation was concealed from psychologists involved in this study; two of the psychologists who provided guidance were also administrators with access to the backend of the software."

11a) If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how NPT: Whether or not administering co-interventions were blinded to group assignment

11a-i) Specify who was blinded, and who wasn't

Specify who was blinded, and who wasn't. Usually, in web-based trials it is not possible to blind the participants [1, 3] (this should be clearly acknowledged), but it may be possible to blind outcome assessors, those doing data analysis or those administering co-interventions (if any).



Does your paper address subitem 11a-i?*


Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, "Allocation was concealed from psychologists involved in this study; two of the psychologists who provided guidance were also administrators with access to the backend of the software."

"Due to the nature of the intervention, participants and psychologists could not be blinded to the assigned treatment condition. Participants were informed about the three conditions and whether they were assigned to either an intervention condition or CAU. It was not specified to participants to which intervention (HG or CG) they were assigned. Psychologists were aware of the participants' intervention condition because they provided participants with personalized feedback in the HG condition and with reminders in both. The assessments were all conducted online and were not accessible for the psychologists (i.e., blinded), except for the pre-session questions that were available through the intervention platform."

11a-ii) Discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator"

Informed consent procedures (4a-ii) can create biases and certain expectations - discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator".



Does your paper address subitem 11a-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Due to the nature of the intervention, participants and psychologists could not be blinded to the assigned treatment condition. Participants were informed about the three conditions and whether they were assigned to either an intervention condition or CAU. It was not specified to participants to which intervention (HG or CG) they were assigned."

11b) If relevant, description of the similarity of interventions (this item is usually not relevant for ehealth trials as it refers to similarity of a placebo or sham intervention to a active medication/intervention)

Does your paper address CONSORT subitem 11b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes: "Participants were informed about the three conditions and whether they were assigned to either an intervention condition or CAU. It was not specified to participants to which intervention (HG or CG) they were assigned."

12a) Statistical methods used to compare groups for primary and secondary outcomes

NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed

Does your paper address CONSORT subitem 12a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes: "Linear mixed models (LMM) were used to estimate treatment effects over time."

12a-i) Imputation techniques to deal with attrition / missing values

Imputation techniques to deal with attrition / missing values: Not all participants will use the intervention/comparator as intended and attrition is typically high in ehealth trials. Specify how participants who did not use the application or dropped out from the trial were treated in the statistical analysis (a complete case analysis is strongly discouraged, and simple imputation techniques such as LOCF may also be problematic [4]).



Does your paper address subitem 12a-i?*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes: "To handle missing values for the main outcomes, multiple imputation was used. The Markov Chain algorithm was employed to impute 50 data sets, with a maximum of 100 iterations for each imputation."

12b) Methods for additional analyses, such as subgroup analyses and adjusted analyses

Does your paper address CONSORT subitem 12b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes: "For the secondary outcomes, only long-term outcomes were analyzed (t5). Bonferroni corrections were applied to all exploratory multilevel models to control for type I error related to multiple testing, while avoiding an increased risk for type II error. "

X26) REB/IRB Approval and Ethical Considerations [recommended as subheading under "Methods"] (not a CONSORT item)




Does your paper address subitem X26-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes: "This study was approved by the medical ethical committee [METC number 2018_085, NL64929.018.18]."

x26-ii) Outline informed consent procedures

Outline informed consent procedures e.g., if consent was obtained offline or online (how? Checkbox, etc.?), and what information was provided (see 4a-ii). See [6] for some items to be included in informed consent documents.



Does your paper address subitem X26-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes: "Participants who scored above the cut-off (see above) on either anxiety and/or depressive symptoms received an email with an online information brochure and informed consent document. Participants could also choose to receive the information brochure and informed consent document through the post. Likewise, informed consent could be signed online, returned by post, or handed in at several "collection points" at the university campus."

X26-iii) Safety and security procedures

Safety and security procedures, incl. privacy considerations, and any steps taken to reduce the likelihood or detection of harm (e.g., education and training, availability of a hotline)



Does your paper address subitem X26-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes: "Ample attention was paid to warrant safety and decrease adverse effects during the trial. For this purpose, a "suicide protocol" was developed, describing in detail what the collaborating psychologists should do in case of an alert, which is available (only in Dutch) upon request (see also Supplement 1 for more details). To monitor for sharp increases in complaints, the PHQ-4 [36] was administered before each treatment session or weekly via email (CAU). Suicide risk was monitored using item three ('feeling down, depressed, or hopeless') of the PHQ-4 and item nine ('thought that you would be better off dead, or of hurting yourself') of the Beck Depression Inventory (BDI)-II [37]."

RESULTS

13a) For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome NPT: The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider in each center

Does your paper address CONSORT subitem 13a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "As can be seen in Figure 1, a total number of 801 participants were eligible and thus randomized across conditions: 269 were allocated to the HG group, 265 to the CG group, and 267 to CAU."

13b) For each group, losses and exclusions after randomisation, together with reasons

Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown in a CONSORT flow diagram)	
Copy and paste relevant sections from the manuscript (include quotes in quotation mar "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study	rks

Yes, this is shown in a CONSORT flow diagram.

13b-i) Attrition diagram

Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in or using the intervention/comparator in each group plotted over time, similar to a survival curve) or other figures or tables demonstrating usage/dose/engagement.

	1	2	3	4	5	
subitem not at all important	0	0	0	۲		essential electie wissen

Does your paper address subitem 13b-i?

Copy and paste relevant sections from the manuscript or cite the figure number if applicable (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

We have amply addressed the attrition rates and user rates, but we have not depicted this in a diagram.

14a) Dates defining the periods of recruitment and follow-up

Does your paper address CONSORT subitem 14a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, we addressed this in the following statement: "The study spanned 3 academic years (2018/19 to 2021/22)"

14a-i) Indicate if critical "secular events" fell into the study period Indicate if critical "secular events" fell into the study period, e.g., significant changes in Internet resources available or "changes in computer hardware or Internet delivery							
1	2	3	4	5			
0	0	0	۲	0	essential		
				S	electie wissen		
	ts" fell int "changes	ts" fell into the stu "changes in comp	ts" fell into the study perio "changes in computer harc	ts" fell into the study period, e.g., si "changes in computer hardware or	ts" fell into the study period, e.g., significant "changes in computer hardware or Internet of 1 2 3 4 5 O O O O O		

Does your paper address subitem 14a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, the COVID-19 pandemic fell within the study period. "First, nearly all participants were included during the COVID-pandemic, which reached its first peak in the Netherlands May 2020. More precisely, only fifteen participants (1.9%) completed the entire study before the onset of the pandemic. Intervention effects may have been distorted due to this crisis, for instance, due to an increase in symptoms during the trial [34]."

14b) Why the trial ended or was stopped (early)

Does your paper address CONSORT subitem 14b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No, this does not apply to our study.

15) A table showing baseline demographic and clinical characteristics for each group

NPT: When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group

Does your paper address CONSORT subitem 15? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This information was provided in the text.

15-i) Report demographics associated with digital divide issues

In ehealth trials it is particularly important to report demographics associated with digital divide issues, such as age, education, gender, social-economic status, computer/Internet/ehealth literacy of the participants, if known.

	1	2	3	4	5	
subitem not at all important	0	0	0	۲	0	essential
					S	electie wissen

Does your paper address subitem 15-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

As this study was conducted among university students (ie. dominantly highly educated, Western European people), this issue was not explicitly addressed.

16) For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups

16-i) Report multiple "denominators" and provide definitions

Report multiple "denominators" and provide definitions: Report N's (and effect sizes) "across a range of study participation [and use] thresholds" [1], e.g., N exposed, N consented, N used more than x times, N used more than y weeks, N participants "used" the intervention/comparator at specific pre-defined time points of interest (in absolute and relative numbers per group). Always clearly define "use" of the intervention.

	1	2	3	4	5	
subitem not at all important	0	0	0	۲	0	essential
					S	electie wissen

Does your paper address subitem 16-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

All analyses were performed on intention to treat basis. Apart from this, we have mentioned the number of sessions done, and the use of optional modules.

16-ii) Primary	[,] analysis	should	be	intent-to-treat
-------	-----------	-----------------------	--------	----	-----------------

Primary analysis should be intent-to-treat, secondary analyses could include comparing only "users", with the appropriate caveats that this is no longer a randomized sample (see 18-i).

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem 16-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, see also 16-i. "Results were analyzed according to the intention-to-treat principle using multiple imputation."

17a) For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)

Does your paper address CONSORT subitem 17a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, we have portrayed all means and standard deviations at all time points, for each group, in tables. Effect sizes were given only with respect to the primary end-points (time*treatment interactions).

17a-i) Presentation of process outcomes such as metrics of use and intensity of use

In addition to primary/secondary (clinical) outcomes, the presentation of process outcomes such as metrics of use and intensity of use (dose, exposure) and their operational definitions is critical. This does not only refer to metrics of attrition (13-b) (often a binary variable), but also to more continuous exposure metrics such as "average session length". These must be accompanied by a technical description how a metric like a "session" is defined (e.g., timeout after idle time) [1] (report under item 6a).

	1	2	3	4	5	
subitem not at all important	0	0	0	۲	0	essential
					S	Selectie wissen

Does your paper address subitem 17a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, apart grom the primary/secondary clinical outcomes, we have mentioned drop out and completion rates.

17b) For binary outcomes, presentation of both absolute and relative effect sizes is recommended

Does your paper address CONSORT subitem 17b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This does not apply to our data.

18) Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory

Does your paper address CONSORT subitem 18?*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

We have presented sensitivity analyses in a separate heading, as exploratory analyses.

18-i) Subgroup analysis of comparing only users

A subgroup analysis of comparing only users is not uncommon in ehealth trials, but if done, it must be stressed that this is a self-selected sample and no longer an unbiased sample from a randomized trial (see 16-iii).

	1	2	3	4	5	
subitem not at all important	0	0	0	۲	0	essential
					S	electie wissen

Does your paper address subitem 18-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, a secondary analysis of those with "sufficient e-health" was part of the sensitivity analysis.

19) All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)

Does your paper address CONSORT subitem 19? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This does not apply as no adverse advents occurred,

19-i) Include privacy breaches, technical problems

Include privacy breaches, technical problems. This does not only include physical "harm" to participants, but also incidents such as perceived or real privacy breaches [1], technical problems, and other unexpected/unintended incidents. "Unintended effects" also includes unintended positive effects [2].

	1	2	3	4	5		
subitem not at all important	0	0	0	۲	0	essential	
					S	electie wissen	

Does your paper address subitem 19-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, technical problems were addressed hands-on, as participants could contact the administrators for this: "Moreover, participants in both online conditions could use the chat/messaging function to ask technical or user-related questions (e.g., problems getting online access)."

19-ii) Include qualitative feedback from participants or observations from staff/researchers

Include qualitative feedback from participants or observations from staff/researchers, if available, on strengths and shortcomings of the application, especially if they point to unintended/unexpected effects or uses. This includes (if available) reasons for why people did or did not use the application as intended by the developers.

	1	2	3	4	5	
subitem not at all important	0	0	0	۲	0	essential
					S	electie wissen

Does your paper address subitem 19-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, apart from COVID-19 we addressed several aspects in the limitations section: "Third, as expressed by some students, the modules were "text heavy" and lacked interactive functionalities, which may have diminished its attractiveness, so this could be improved. Yet, the intervention had been adapted especially for students, and the text was enriched by elements of persuasive design, which are known to increase adherence, such as creating an overview, use of metaphors, and creating a sense of control and purpose [58]. Fourth, in hindsight, we might have recruited more psychologists for guidance, which would have resulted in swifter feedback, "


DISCUSSION

22) Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence

NPT: In addition, take into account the choice of the comparator, lack of or partial blinding, and unequal expertise of care providers or centers in each group

22-i) Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use)

Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use).



Does your paper address subitem 22-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, we start the introduction with a reiteration of study aims, and our main findings: "In this study, we compared two types of online interventions with CAU, both regarding the short and long-term outcomes in a large sample of university students with elevated levels of depression and/or anxiety symptoms. Overall, reductions in anxiety and depression were seen in all three conditions over time, yet no significant differences between conditions were observed over time. "

22-ii) Highlight unanswered new questions, suggest future research Highlight unanswered new questions, suggest future research.								
	1	2	3	4	5			
subitem not at all important	0	0	0	۲	0	essential		
					S	electie wissen		

Does your paper address subitem 22-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, we made repeated referrals to future research, such as: 'Future studies could test the hypothesis whether human guidance indirectly impacts symptom outcomes through its effect on adherence (mediation analysis)."

20) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses

20-i) Typical limitations in ehealth trials

Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trials often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
					S	electie wissen

Does your paper address subitem 20-i? *


Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, in a large section we addressed eight limitations of our study that deserve attention.

21) Generalisability (external validity, applicability) of the trial findings NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial

21-i) Generalizability to other populations

Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations



Does your paper address subitem 21-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, we explicitly addressed this by referring to the representativeness of this sample: "Third, we included students with elevated levels of symptoms, with over a quarter of the students presenting with at least one potential mental disorder, which makes this a representative sample of students in terms of burden of disease [3]."

21-ii) Discuss if there were elements in the RCT that would be different in a routine application setting

Discuss if there were elements in the RCT that would be different in a routine application setting (e.g., prompts/reminders, more human involvement, training sessions or other cointerventions) and what impact the omission of these elements could have on use, adoption, or outcomes if the intervention is applied outside of a RCT setting.

	1	2	3	4	5	
subitem not at all important	0	0	0	۲	0	essential
					S	electie wissen

Does your paper address subitem 21-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This is a good point which we possibly have not sufficiently addressed. We think that the delivery of treatment in this trial differs from routine application in that in regular mental health care settings, web-based treatments are delivered in combination with face to face sessions.

OTHER INFORMATION

23) Registration number and name of trial registry

Does your paper address CONSORT subitem 23? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes: "Trial registration: NL7328/NTR7544 (ICTRP)" (Abstract)

24) Where the full trial protocol can be accessed, if available

Does your paper address CONSORT subitem 24? *

Cite a Multimedia Appendix, other reference, or copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, we refer to the protocol paper in the methods section.

25) Sources of funding and other support (such as supply of drugs), role of funders

Does your paper address CONSORT subitem 25? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, we mention that the university funded our study.

X27) Conflicts of Interest (not a CONSORT item)

X27-i) State the relation of the study team towards the system being evaluated

In addition to the usual declaration of interests (financial or otherwise), also state the relation of the study team towards the system being evaluated, i.e., state if the authors/evaluators are distinct from or identical with the developers/sponsors of the intervention.

	1	2	3	4	5	
subitem not at all important	0	0	0	۲	0	essential
					S	electie wissen

Does your paper address subitem X27-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This item was not explicitly addressed, but should be clear from the information provided in the paper.

About the CONSORT EHEALTH checklist

As a result of using this checklist, did you make changes in your manuscript? *

) yes, major changes

) yes, minor changes

no

What were the most important changes you made as a result of using this checklist?

N/A, as the paper was already accepted for publication, and we addressed the majority of issues.

How much time did you spend on going through the checklist INCLUDING making * changes in your manuscript

over two hours (!), which is too long in my opinion. This checklist is longer than the paper it applies to.

As a result of using this checklist, do you think your manuscript has improved? *

) yes

🗩 no

) Anders:

Would you like to become involved in the CONSORT EHEALTH group? This would involve for example becoming involved in participating in a workshop and writing an "Explanation and Elaboration" document yes no Anders: Selectie wissen Any other comments or questions on CONSORT EHEALTH No, I have no further comments. STOP - Save this form as PDF before you click submit To generate a record that you filled in this form, we recommend to generate a PDF of this page (on a Mac, simply select "print" and then select "print as PDF") before you submit it. When you submit your (revised) paper to JMIR, please upload the PDF as supplementary file. Don't worry if some text in the textboxes is cut off, as we still have the complete information in our database. Thank you!

Final step: Click submit ! Click submit so we have your answers in our database!

Verzenden

Formulier wissen

Verzend nooit wachtwoorden via Google Formulieren.

Deze content is niet gemaakt of goedgekeurd door Google. <u>Misbruik rapporteren</u> - <u>Servicevoorwaarden</u> - <u>Privacybeleid</u>

Google Formulieren

E